HLB Group announced Wednesday it will present the latest research findings on its key cancer pipelines at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego from April 17 to 22.
AACR is one of the world's three largest cancer conferences alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). The event brings together cancer researchers and pharmaceutical and biotech companies worldwide to share cutting-edge oncology research.
Verismo Therapeutics, a U.S. subsidiary of HLB Innovation, will present interim results from its Phase 1 U.S. clinical trial of SynKIR-110, a chimeric antigen receptor T-cell (CAR-T) therapy for solid tumors. While the clinical trial design and progress have been introduced at several global conferences last year, this marks the first disclosure of actual clinical data.
SynKIR-110 was developed using Verismo's proprietary KIR-CAR platform technology. The therapy is designed to address T-cell exhaustion caused by excessive T-cell activation, a known limitation of existing CAR-T treatments. Industry attention on safety and efficacy data is growing accordingly.
Elevar Therapeutics, another HLB subsidiary, will present analysis comparing the FGFR2 selectivity of its targeted cancer drug rilapugratnib against existing pan-FGFR inhibitors. Rilapugratnib demonstrated efficacy and safety through global Phase 2 clinical data at the ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) in January, showing potential as a best-in-class therapy.
Rilapugratnib received Breakthrough Therapy Designation in 2023. Based on Phase 2 results, the company completed its application to the U.S. Food and Drug Administration in January. HLB expects the additional analysis at AACR will serve as evidence highlighting rilapugratnib's differentiation in the commercialization process.
"Through this AACR presentation, we plan to more clearly demonstrate the technological differentiation and clinical value of HLB Group's next-generation cancer pipelines to the global market," said Nam Kyung-sook, Executive Director of Bio Strategy Planning at HLB Group. "Based on validated clinical and preclinical data, we will refine our global development strategy and accelerate clinical development to secure sustainable technological competitiveness in the next-generation cancer drug sector."